Japanese reconstructed breasts with stem cells

Japanese scientists have tested a new method of correcting errors after removal of the breast. As the "building blocks" they used their own fat, mixed with the stem cells, according to AP. The new technique of breast reconstruction, developed by the American company Cytori Therapeutics, has been tested on 21 women. All participants previously had a segmentectomy of breast cancer (lumpectomy) - to remove surgical removal of the tumor and a minimal amount of surrounding tissue. This process is as gentle as the complete removal of the breast is performed. To the resulting lack investigator Keizo Sugimachi (Keizo Sugimachi) and his colleagues used a patient's own fat tissue filling during liposuction get stomach and thighs. A portion of the fat was used to stem receiving form new fat cells and blood vessels. Stem cells were mixed with the remaining fat tissue and in the chest area of the defect, the researchers reported. Report on the results of the study were presented at the symposium Keizo Sugimachi for breast cancer, in San Antonio. According to him, the procedure was well tolerated by all women and is considered safe. None of the subjects had no tissue rejection and improves the appearance of the breast significantly. After eight months of treatment, 80% of patients were satisfied with the results reported Sugimachi. Only in the United States each year more than 100 thousand operations segmental resection of the breast. These operations lead to a significant deformation of the breast, which is amplified in the course of time. At the same time, the methods of defect correction is practically nonexistent. Particular women can not the implants for the complete removal of the breast (mastectomy) used. In such a situation is practically the only alternative is the chest by the operation (eg, reduction of healthy breasts change, back muscles on the affected breast), which is associated with the formation of scars and other negative reactions to correct. The technique tested by Japanese scientists, is considered promising. However, further research is needed. The following year, is planning two major clinical trials in Europe and Japan are carried out, said the representative of the company Cytori Therapeutics.